Perioperative nivolumab plus chemotherapy misses co-primary endpoints in muscle-invasive bladder cancer

Study · OncLive · 2026-10-23. Number 1 in the UrologyWatch Top 5 for October 27, 2026.

This phase 3 trial testing neoadjuvant chemotherapy plus nivolumab followed by adjuvant nivolumab against chemotherapy alone in muscle-invasive bladder cancer did not meet its co-primary endpoints. The negative result contrasts with other perioperative immunotherapy regimens that have shown benefit in this disease setting.

Why it matters: This negative randomized trial indicates that not all perioperative immunotherapy combinations improve outcomes in muscle-invasive bladder cancer, and it contrasts with positive results from other regimens presented at…

Limitation: Meeting presentation; full peer-reviewed details may follow.

Source: OncLive

The full October 27, 2026 edition · Today's urology news